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The only existing preventive measure against American trypanosomosis, or Chagas disease, is the control of the
transmitting insect, which has only been effective in a few South American regions. Currently, there is no vaccine
available to prevent this disease. Here, we present the clinical and cardiac levels of protection induced by
expression to Trypanosoma cruzi genes encoding the TcSP and TcSSP4 proteins in the canine model. Physical
examination, diagnostic chagasic serology, and serial electrocardiograms were performed before and after
immunization, as well as after experimental infection. We found that immunization with recombinant plasmids
prevented hyperthermia in the acute phase of experimental infection and produced lymphadenomegaly as an
immunological response against the parasite and additionally prevented heart rate elevation (tachycardia) in the
acute and/or chronic stages of infection. Immunization with T. cruzi genes encoding the TcSP and TcSSP4 antigens
diminished the quality and quantity of the electrocardiographic abnormalities, thereby avoiding progression to
more severe developments such as right bundle branch block or ventricular premature complexes in a greater
number of dogs.Introduction
Chagas disease (CD) is endemic to the American contin-
ent, and 25 million people are at risk in Latin America
[1]. There are several T. cruzi reservoirs; the dog is the
most important domestic species in the infective cycle,
mainly because the dog serves as a considerable source
of nourishment for the triatomine insects, and the fact
that the dogs eat infected bugs, thus increasing the risk
of transmission within human dwellings [2]. It is esti-
mated that there are 3500 new cases per year in Mexico
[3], and the dog population seroprevalence is between
1.6 and 21%, depending on the geographical region of
the country [4-7]. Therefore, there is a significant* Correspondence: mini_arce@yahoo.com.mx
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distribution, and reproduction in any mediumnumber of dogs that could be acting as reservoirs, thus
creating a public health problem.
Currently, a major stumbling block for research efforts
striving to elucidate the mechanisms of acute and
chronic CD pathogenesis is the lack of a suitable animal
model. It has been shown that dogs develop diffuse
chronic myocarditis with histological and electrocardio-
graphic changes that are also found in humans [8-12];
therefore, this animal represents a useful experimental
model that is gaining attention in the CD research field.
The clinical signs in Chagas-infected dogs during both
the chronic and acute stages closely resemble the symp-
toms of human disease [13-15].
In spite of the success of vaccines, there are still nu-
merous pathogens, and in particular protozoan parasites,
against which there are still no effective vaccine. Specif-
ically, vaccine development against CD has been dramat-
ically limited because of an extensive debate on the
mechanisms involved in disease pathology. However, theed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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coding foreign proteins could lead to endogenous pro-
tein biosynthesis and a specific immune response against
it has resulted in new directions for vaccine develop-
ment, particularly if the vaccine is capable of inducing a
Th1 immune response and the activation of cytotoxic
CD8+T cells [16].
In a previous study that used a murine model, plasmid
pBCSSP4 and pBCSP immunizations, which contained
the genes encoding the Trypanosoma cruzi TcSSP4 and
TcSP proteins, respectively, were found to be effective at
inducing antibodies that were augmented after the boost.
Protection during the acute phase of the disease was
partial because there was a 64% reduction in parasitemia
with plasmid pBCSSP4 and a 72.9% reduction with
pBCSP injection compared to controls. Survival was 75%
in pBCSSP4-immunized mice and 100% in those immu-
nized with pBCSP. This study demonstrated protection
during the chronic phase of the disease because histo-
logical analysis showed that the immunization dimi-
nished cardiac damage [17,18].
In this study, the canine model was used to determine
the level of clinical protection given by immunization
with pBCSSP4 and pBCSP plasmids to protect against
experimental CD in dogs. A general physical exami-
nation was performed for each subject with special
regards for body temperature, exploration of lymph
nodes, and heart rate; electrocardiographic recordings
were performed to evaluate cardiac electrical conduction
abnormalities during the acute and chronic stages.
Materials and methods
Animals
Thirty male and female Beagle dogs, aged 5 (± 1) months
and weighing 8.52 (± 1.55) kg, were used; all animals had
been immunized against the main canine diseases, and
had received intestinal deworming. A standardized
enzyme-linked immunosorbent assay (ELISA) [19] was
used to diagnose CD in the dogs to rule out any previous
natural infections. Animal handling followed the estab-
lished guidelines of the International Guiding Principles
for Biomedical Research involving Animals and the
Norma Oficial Mexicana [20] Technical Specifications for
the Care and Use of Laboratory Animals, and the experi-
mental protocol was approved by the Bioethics Committee
of the Instituto Nacional de Cardiología, Ignacio Chávez.
Plasmid DNA construction, purification and immunization
The gene encoding TcSSP4 (amastigote-specific protein)
was obtained from the pBluescriptSk-Am230 plasmid
[21] as a 2.2 kb Eco RI (Boehringer Mannheim) frag-
ment. The gene encoding TcSP (trans-sialidase protein)
was released from pBluescriptSk-A83 plasmid (Rosales-
Encina JL, unpublished observations) as a 6.0 kb Eco RIfragment. The complete open reading frames of the T.
cruzi TcSSP4 and TcSP genes were inserted into the mul-
tiple cloning site of the commercially available
eukaryotic expression vector pBK-CMV (Stratagene) to
generate 2 constructs, pBCSSP4 and pBCSP, respectively.
The genes were placed under the control of the cyto-
megalovirus promoter and were inserted downstream of
a Kozak consensus sequence in-frame with an initiation
codon. Colonies containing the plasmids with the insert
in the correct orientation were selected. The plasmids
were grown in XL1-Blue E. coli and purified using the
QIAGEN Plasmid Mega Kit in accordance with the
manufacturer’s instructions. The expression of TcSSP4
and TcSP was analyzed using HeLa cells in vitro prior to
an immunization trial of the dogs. The recombinant
plasmids or control empty plasmid were transfected to
HeLa cells using a transfection reagent (FuGENE 6,
Boehringer Mannheim) in accordance with the protocol
provided by the manufacturer. The expression of TcSSP4
and TcSP was analyzed by Western blotting using an
anti-SSP4 or anti-SP polyclonal antibody as a primary
antibody 2 days after transfection. Five experimental
groups with 6 dogs each were made, and the fol-
lowing were infected 15 days after the corresponding
treatment: 1) pBCSP plasmid-immunized, 2) pBCSSP4
plasmid-immunized, 3) pBK-CMV empty cloning vector-
immunized, and 4) mock-immunized with physiologic
saline solution (SS). The fifth group corresponding to the
control was not subjected to any experimental procedure.
The dogs were immunized with DNA twice at 15-day
intervals by intramuscular injection between the semi-
tendinosus and semimembranosus muscles of the pelvic
limbs using a 3-mL syringe with a 21 G × 32 mm needle.
Each single dose consisted of 500 μg DNA dissolved in
500 μL SS.Experimental inoculation and confirmation of T. cruzi
infection
A well-characterized Mexican T. cruzi Ninoa strain
maintained by serial passage in reduviid vectors was
employed [22]. The infection was performed 2 weeks
after the last immunization by intraperitoneal injection
with 5 × 104 metacyclic trypomastigotes per animal,
which were obtained from urine and feces of triatomines
and resuspended in SS. To confirm experimental T.
cruzi infection in all groups, parasitemia was determined
microscopically by examining freshly isolated blood sam-
ples collected from the brachiocephalic vein every third
day, starting on day 10 post-infection until day 65 post-
infection. Standardized ELISA and indirect immuno-
fluorescence (IIF) were performed using methods
described previously [19] to confirm experimental T.
cruzi infection 2 months after challenge.
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rate determinations
General physical examinations were performed. For body
temperature evaluation, a digital rectal thermometer
(MicrolifeW) was used, and all peripheral lymph nodes
(popliteal, submaxilary, prescapular, axillary and inguinal)
were palpated and scored by a single person (MMPL) who
was blinded to the experimental groups. Body temperature
and peripheral lymph node determinations were registered
4 times each according to the following chronology of the
experimental scheme: prior to the start of immunization
(t1), before infection (t2), at the acute phase of CD (t3)
and at the chronic phase of CD (t4), while heart rates were
determined at t1, t3 and t4.
Electrocardiography
Prior to the start of immunization (t1) and during the
acute (t3) and chronic stages (t4) of the disease, electro-
cardiographic recordings were performed. Three bipolar
standard leads (I, II and III), 3 augmented unipolar limb
leads (aVR, aVL, and aVF), and 4 unipolar precordial
thoracic leads (CV5RL, CV6LL, CV6LU and V10) were
recorded. The dogs were held by an attendant in right
lateral recumbency, and no chemical restraint was
employed. For each tracing, the voltage was standardized
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Figure 1 rSSP4 and rSP protein expression in the HeLa plasmid trans
pBCSSP4 plasmid transfected cell extracts; samples were taken at different
56 h. The membrane was probed with the anti-MBP::SSP4 antibody. (C) SDS
cell extracts; samples were taken at different time points; Lanes: MWM, mo
membrane was probed with the anti-epimastigote whole extract antibody
control empty vector pBK-CMV HeLa transfected cells.Statistical analysis
Continuous variables, such as body temperature and
heart rate, were analyzed using the two-way ANOVA
statistical test, establishing a correlation between each
treatment group and the control group. The lymph node
palpation was analyzed with a Kruskal-Wallis test.
Results
HeLa cell transfection
TcSSP4 protein was present in the pBCSSP4 plasmid
HeLa transfected cells as early as 8 h and up to 56 h
post transfection, with an optimal expression level be-
tween 24 and 48 h (Figures 1a and 1b). The TcSP protein
expression in the eukaryotic system was determined by
immunoblotting, detecting its presence only at 24 and
48 h post transfection with plasmid pBCSP (Figures 1c,
and 1d). These results demonstrate that the TcSSP4 and
TcSP genes were correctly subcloned into the pBK-CMV
vector and that the recombinant plasmids are capable of
expression in eukaryotic cells.
Diagnosis of CD in dogs
All of the experimental animals were negative for the cha-
gasic serology test at t1 and were also in excellent health,
which confirmed the absence of CD before any manipu-
lation. Parasitemia was too low to be quantified, and2  3  4       5   6      7 8      9 
rSP




fected cells. (A) SDS-PAGE and (B) western blot analysis of the
time points; Lanes: 2 and 3, 8 h; 4 and 5, 24 h; 6 and 7, 48 h; 8 and 9,
-PAGE and (D) western blot analysis of the pBCSP plasmid transfected
lecular weight marker; 2, 8 h; 3, 24 h; 4, 48 h; 5, 56 h, and 6, 72 h. The
. Lanes 1 in (A), (B), (C), and (D) are the samples corresponding to
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tion. The limit of detection was 200 to 400 parasites/mL
of blood sample intermittently throughout all analysis.
All infected/unimmunized dogs exhibited parasitemia
starting on day 22 and lasting until day 55 post-infection,
whereas the parasitemia of immunized/infected dogs
occurred over a shorter time period, from day 32 to 46
post-infection (Table 1). At two months post-inoculation,
the infection of T. cruzi was diagnosed by the ELISA
method and was confirmed by IIF in all infected/
unimmunized dogs (data not shown).Effect of DNA immunization on body temperature
During T. cruzi Ninoa strain infection, the characteristic
acute stage was demonstrated by an elevation in body
temperature in the SS mock-immunized and infected
group. The recombinant plasmids in immunized animals
avoided the temperature increase, thus demonstrating a
protective effect of the plasmid DNA by eliminating this
clinical sign in the acute stage of CD (Figure 2).Table 1 Parasitemia detection in DNA-immunized dogs with e
Group Dog
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6 + + +
+ Detection of 1 or 2 parasites per blood sample of fresh drop examination.Effect of experimental immunization on lymph nodes
Lymphadenomegaly in the group immunized with
pBCSP plasmid was present in 50% of the animals at t2,
increasing to 67% during t3 (Table 2). Approximately
50% of the pBCSSP4 immunized/infected dogs had
lymph node enlargement at t2; however, all dogs showed
significant lymphadenomegaly during the acute stage of
the disease (t3, Table 2). This suggests that the lympha-
denomegaly could be a symptom of both the infection
and the reaction of vaccine, being that lymph nodes are
major sites of antigen capture, detection, and initial
responses during an adaptative immune response.
The lymph node enlargement after the plasmid pBK-
CMV immunization was noticeable in 17% of the dogs at
t2, and in the acute stage of T. cruzi infection (t3) the num-
ber of animals with lymph node enlargement notably grew
up to 83%. These data indicate that the empty cloning vec-
tor immunization had no clinical effect on the immune sys-
tem, whereas the parasitic infection did (Table 2).
All dogs inoculated with SS and later experimentally
infected had lymph node enlargement only during t3,xperimental T. cruzi infection
Days after inoculation








+ + + + +
+ + +




























Figure 2 Body temperature of DNA-immunized dogs with experimental T. cruzi infection. Rectal temperature recordings from each
experimental group (plasmid DNA immunized- and SS mock-immunized dogs) were compared with those of the control group (uninfected
healthy animals). The values are the average of the temperature recordings ± S.D. Two-way ANOVA statistical test (* P ≤ 0.05).
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tem, which manifests as lymphadenomegaly (Table 2).
Effect of plasmid DNA immunization on heart rate
The pBCSP plasmid-immunized/infected group did not
have an increase in heart rate post-infection (t3 or t4)
(Figure 3). The pBCSSP4 plasmid-immunized/infected
group had a significant increase in heart rate during t3
but did not reach the 160 beats per minute that would
indicate tachycardia; at t4 one dog had tachycardia,
representing no statistical significance (Figure 3).
Immunization with the pBK-CMV plasmid was unable
to inhibit heart rate increases at any stage of the infec-
tion, showing a significant increase in pulse rate during
both t3 and t4, as well as mock-immunized dogs with SS
(Figure 3). These results indicate that immunization with
the pBCSSP4 plasmid had a protective effect only during
the chronic stage of the experimental infection; whereas
immunization with the pBCSP plasmid had a greater
protective effect since there were no increases in heart
rate during both stages of CD.
Effect of plasmid DNA immunization on heart electrical
conduction during CD
Before immunization and challenge, 23% of the animals
had sinus tachycardia, which was likely due to a physio-
logical state associated with the restraint procedures
used during the electrocardiographic recordings.
Seventeen percent of the dogs belonging to the
pBCSP-immunized/infected group at t3 (Table 3)
showed an increased duration of the P wave (0.06 s vs.
0.04 s), the absence of T waves in some records, andtachycardia. A P-R interval longer than the normal 0.12
s (0.14 s) was observed in 17% of the animals of this
same group at the acute stage of CD. The conditions
associated with these findings are intraventricular con-
duction defects, such as right or left bundle branch
block (BBB) or ventricular enlargement, as well as an
atrioventricular (AV) block. At t4 in this group, patterns
characteristic of left ventricular enlargement, such as an
abnormal left electrical axis deviation, were observed.
Additionally, the R wave exceeded 2.5 mV in CV6LL (3.0
mV), and the R wave in lead I was greater than in lead
III and aVF in 17% of the dogs.
An S-T segment elevation of 0.5 mV in leads II, III,
aVF and CV6LL was observed in 17% of the dogs at t3 in
the pBCSSP4-immunized/infected group (Table 3),
which could suggest myocardial infarction and/or peri-
carditis. At t4, several P waves were not followed by
QRS-T complexes in one of the dogs in this group, sug-
gesting a second-degree AV block. At this time, the
same dog that showed a possible myocardial infarction
and/or pericarditis at t3 showed a wide QRS complex
(0.06 s vs. 0.05 s), an inverted QRS complex in leads
aVR, aVL and CV5RL, and a small Q in lead I (0.05 mV)
indicative of left BBB, which might be caused by a myo-
cardial disease such as the dilated form of chronic Cha-
gas cardiomyopathy.
Reversal in polarity of the T wave combined with an R
wave greater than 2.5 mV in leads II, III, aVF, and CV6LL
and a mean electrical axis deviation (MEAD) in the frontal
plane of less than +40° were found in 50% of the animals
from the pBK-CMV-immunized/infected group (Table 3) at
t3. These features suggested left ventricular enlargement
Table 2 Lymph node palpation scores from DNA-immunized dogs with experimental T. cruzi infection
Group Dog Lymph node inflammation (score)1 and percentage of dogs from each group with lymphadenomegaly
Basal t1 % Postimmunization t2 % Acute stage t3 %
pBCSP 1 0 0 0 50 0 67
2 0 0 0
3 0 0 1
4 0 2 1
5 0 1 1
6 0 1 2
pBCSSP4 1 0 0 0 50 1 100*
2 0 1 2
3 0 2 1
4 0 1 1
5 0 0 2
6 0 0 2
pBK-CMV 1 0 0 0 17 0 83*
2 0 0 1
3 0 0 1
4 0 0 2
5 0 1 1
6 0 0 1
SS mock-immunized 1 0 0 0 0 1 100*
2 0 0 1
3 0 0 1
4 0 0 1
5 0 0 1
6 0 0 1
1The severity of inflammation in lymph nodes was scored on a scale from 0 to 2. A score of 0 indicated normal; 1, slightly swollen; and 2, very enlarged (scores of
1 and 2 were considered to be indicative of lymphadenomegaly). baseline = t1, prior to the start of the immunization, Postimmunization = t2, before the infection
at 15 days post-immunization, and Acute stage = t3, at 30 days post-infection. Popliteal, submaxillary, axillary and inguinal lymph nodes were palpated and means
were compared with the Kruskal-Wallis test. Differences were considered as significant when P ≤ 0.05.
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athy caused by CD. Reversal in polarity of the T wave in
33% of the animals occurred again at the chronic stage of
CD (t4), of which one dog (17%) showed a T wave that was
increased more than 25% than the R wave, and QRS com-
plexes had large wide S waves in leads I, II, III, aVF, CV6LL,
and CV6LU that suggested right BBB.
Approximately 33% of the dogs from the SS-inoculated/
infected group (Table 3) during t3 showed a MEAD to
the left of the frontal plane combined with an R wave
that exceeded 2.5 mV in lead CV6LL and an R wave in
lead I greater than in leads III and aVF, suggesting left
ventricle enlargement; two of these animals also had
arrhythmia and a prolonged Q-T interval that suggested
intraventricular conduction defects. The features asso-
ciated with left ventricle enlargement such as a MEAD to
the left of the frontal plane combined with an R wave
above 2.5 mV in lead CV6LL and an R wave in lead I
greater than in leads III and aVF appeared in 50% of thedogs during t4 in this group. Electrocardiographic fea-
tures associated with ventricular premature complexes
(VPC), such as rhythm irregularity, QRS complex pre-
mature, bizarre, and of large amplitude, and a T wave
directed opposite the QRS, were also present in 17% of
the dogs; reversal in polarity of the T wave in 33% of the
animals occurred at this time (t4).
The control group animals were not subjected to any
experimental procedure and exhibited normal electro-
cardiogram (EKG) at all times.Discussion
The results obtained in this study show classic clinical
signs of CD described by others [6,15,25,26]. The sample
size was appropriate for the DNA vaccination canine
model in CD and was similar to what has been reported






























Figure 3 Heart rate of DNA-immunized dogs with experimental T. cruzi infection. Heart beat recordings from each experimental group
(plasmid DNA immunized- and SS mock-immunized dogs) were compared with those of the control group (uninfected healthy animals). Heart
rates exceeding 160 beats per minute were considered tachycardic. The values represent the average of the heart rate recordings ± S.D. Two-way
ANOVA statistical test (* P ≤ 0.05).
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temperature increases during the acute phase of the dis-
ease. The hypothesis of glandular hypertrophy in the
murine model during the acute stage of CD has been
reported, mainly because of numerous parasite nests in
the gland parenchyma with atrophy of secretory struc-
tures [30]. This event could have taken place in our
model; however, we were unable to confirm this since
no histological analysis during this phase of the present
study was performed. The dogs immunized with the re-
combinant plasmids had clinically evident immune
responses as evidenced by lymph node enlargement,
however, during the post-infection period, the lymph-
adenopathy was less noticeable. To mount an immune
response, lymphocytes must re-circulate between the
blood and lymph nodes, recognize antigens upon con-
tact with specialized presenting cells, proliferate to ex-
pand a small number of clonally-relevant lymphocytes,
differentiate to antibody-producing plasma cells or ef-
fector T cells, exit from lymph nodes, migrate to tissues,
and engage in host-protective activities such as lympha-
denomegaly or fever [31]. Alternatively, fever has not
been established as a constant sign of CD in dogs, but
other physical signs such as lymph node enlargement al-
ways occur [13-15].
In dogs, the tachyarrhythmias have been documented
in a continuous or paroxistic (intermittent) manner andare associated with several etiologies, including dilated
myocardiopathy, which can be caused by CD, hyper-
trophic myocardiopathy, endocarditis, valvular disease,
congenital defects, cardiac tumors, etc. These may
worsen and progress to heart failure, which may result
in death [32]. In our study, immunization with the re-
combinant plasmids was able to halt the heart rate in-
crease during the acute and/or chronic stages of CD,
which diminished tachyarrhythmia presentation.
Electrocardiographic tracings were analyzed according
to the published data in canine and feline cardiology
[23,24] and our results can be compared to human
patients with CD [33-36]. Some electrocardiographic
findings observed in this study are consistent with the
most frequent electrocardiographic features reported
when the canine model has been used in CD studies
[6,8,15,25,26], such as myocardial infarction and/or peri-
carditis, second-degree AV block, left ventricle enlarge-
ment (dilation or hypertrophy), left and right BBB, and
VPC.
In disagreement with findings reported by others
[8,9,26,28], we did not observe any severe life-
threatening arrhythmias, which is likely due to the strain
used. Any dog infected with the T. cruzi Ninoa strain
exhibited clinical signs that were severe enough to result
in death. We chose the Ninoa strain as a reference
Mexican strain, whose characterization fulfilled the
Table 3 Abnormal electrocardiographic features in DNA-immunized dogs with experimental T. cruzi infection
GROUP 3 MONTHS PI




DOGS/n (%) 6 MONTHS PI






pBCSP Long P wave
(0.06 s vs. 0.04 s a),




1/6 (17%) MEAD to the left,
tall R wave in CV6LL
(3.0 mV vs. 2.5 mVa),
R wave greater in lead





(0.14 s vs. 0.12 s a)
AV block 1/6 (17%)
pBCSSP4 Elevated S-T segment in l
eads I, III, aVF and CV6LL










(0.06 s vs. 0.05 sa),
inverted QRS complex
in leads aVR, aVL, and
CV5RL, and a small Q
in lead I (0.05 mV)
Left BBB 1/6 (17%)
pBK-CMV Reversal polarity of the T wave,
R wave greater than 2.5 mV in




3/6 (50%) Reversal polarity
of the T wave
Most often abnormal
if it is found on
serial EKG
2/6 (33%)
+ T wave more than 25%
larger than the R wave,
QRS complex with S wave
in leads I, II, III, aVF,
CV6LL and CV6LU
Right BBB 1/6 (17%)
MEAD to the left, R wave
exceeded of 2.5 mV in
lead CV6LL, R wave in lead I








MEAD to the left, R wave
exceeded of 2.5 mV in lead
CV6LL, R wave in lead I greater
than in leads III and aVF
Left ventricle
enlargement
2/6 (33%) MEAD to the left, R wave
exceeded of 2.5 mV in lead
CV6LL, R wave in lead I








1/6 (17%) Rhythm irregular,
QRS complex premature,
bizarre, and of large
amplitude, T wave
directed opposite the QRS
VPC 1/6 (17%)
+ prolonged Q-T interval Intraventricular
conduction
defects
1/6 (17%) Reversal in polarity
of the T wave
Most often abnormal




a Reference values [23,24].
BBB bundle branch block.
AV atrioventricular.
MEAD mean electrical axis deviation.
VPC ventricular premature complexes.
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biological behavior, tissue tropism, and virulence in a
susceptible model [22]. Here, we demonstrate that the
Ninoa strain of T. cruzi is able to establish an infection
with the development of some characteristic clinical
signs of acute and chronic stages of CD as described in
dogs [13-15].
In a previous study with mice immunized with the
pBCSP and pBCSSP4 plasmids, the T. cruzi TcSP and
TcSSP4 genes were also effective at inducing antigen-specific antibodies that recognized the surface of T. cruzi
and produced a Th1 immune response, which conferred
significant protection against T. cruzi experimental in-
fection in BALB/c mice [17,18]. Our results indicate that
the protective effect provided by the TcSP and TcSSP4
genes was similar; however, immunization with the
pBCSP plasmid avoided heart rate increases in both
stages of the infection and prevented severe heart con-
duction abnormalities such as myocardial infarction,
second-degree AV block or left BBB. This plasmid
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present in all three forms of T. cruzi and is recognized
by sera from chagasic patients, unlike the TcSSP4 gene
that codes for a glycoprotein associated with the trans-
formation of trypomastigotes into amastigotes [37].
Thus, the slight difference in the protective effect is
likely because the TcSP gene induces immunity against
all forms of the parasite, whereas the TcSSP4 gene only
does so against a stage-specific surface antigen present
on the amastigote form. Further studies of immuniza-
tions with the two plasmids in combination are required
to determine if there is a possible synergistic effect.
We conclude that plasmid DNA vaccination with T.
cruzi genes induces a moderate level of protection in
immunized dogs because this strategy 1) avoids acute
phase fever, 2) induces an immune response that mani-
fests as lymph node enlargement as part of host-
protective activity, 3) avoids heart rate increases during
the acute and/or chronic stages, and 4) most interest-
ingly, halts the symptomatic progression to severe heart
conduction abnormalities.
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